Document text
Principal Investigator: DEBORAH DOROSHOW
Organization: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Fiscal Year: 2024
Award: $60,000
Funding agency: National Cancer Institute
Deborah Doroshow, MD, PhD is a medical oncologist and clinical investigator at the Tisch Cancer Institute,
Icahn School of Medicine at Mount Sinai who specializes in thoracic oncology and histology-agnostic early
phase drug development. This application to the Early Career Cancer Clinical Investigator Award (ECIA) P30
Administrative Supplement (ECIA) describes Dr. Doroshow’s intent to expand her clinical trial research and
leadership activities in 1) the Early Therapeutics Clinical Trials Network (ETCTN), 2) the Southwest Oncology
Group (SWOG), and 3) the Division of Hematology and Oncology at Mount Sinai. In the ETCTN, she will
become principal investigator of the existing Mount Sinai Early Drug Development Opportunity (EDDOP) grant.
In that role, she will collaborate with junior faculty and hematology/oncology fellows to open existing ETCTN
early phase clinical trials and will provide guidance and support regarding the submission of novel study
concepts. As an individual investigator, she will submit at least one original early phase study concept to CTEP
for consideration. As a member of the SWOG lung committee, Dr. Doroshow will co-chair a LUNG MAP
substudy of trastuzumab deruxtecan in patients with advanced ERBB2 amplified NSCLC. She will join the
locally advanced lung cancer committee and participate in ongoing efforts to analyze genomic characteristics
of patient participants in previous and ongoing SWOG thoracic oncology trials. In the Tisch Cancer Institute
and Division of Hematology and Medical Oncology, Dr. Doroshow will serve on the Data Safety Monitoring
Committee and continue to lead the Investigator Initiated Trial (IIT) incubator workshops and serve on the IIT
review committee. Her research and institutional work on improving the diversity of clinical trial participants will
influence efforts in these three domains.
Terms: <Administrative Supplement><Advanced Cancer><Advanced Malignant Neoplasm><Anti-ERB-2><Anti-HER2/c-erbB2 Monoclonal Antibody><Anti-c-ERB-2><Anti-c-erbB2 Monoclonal Antibody><Anti-erbB-2><Anti-erbB2 Monoclonal Antibody><Anti-p185-HER2><Area><CTEP><Cancer Therapy Evaluation Program><Cancers><Center Core Grants><Characteristics><Clinical Investigator><Clinical Investigator Award><Clinical Research><Clinical Study><Clinical Trials><Collaborations><Data><Doctor of Philosophy><ERBB2><ERBB2 gene><ET-CTN><Early Therapeutic-Clinical Trials Network><Educational workshop><Faculty><Genomics><Goals><Grant><HER -2><HER-2><HER2><HER2 Genes><HER2 Monoclonal Antibody><HER2/neu><Hematology><Herceptin><Histology><Incubators><Individual><Institution><Investigators><K08 Mechanism><K08 Program><Knowledge><Leadership><Lung><Lung Respiratory System><Malignant Neoplasms><Malignant Tumor><Malignant Tumor of the Lung><Malignant neoplasm of lung><Medical Oncologist><Medical Oncology><MoAb HER2><Monitor><NCI Organization><NEU Oncogene><NEU protein><NSCLC><NSCLC - Non-Small Cell Lung Cancer><National Cancer Institute><Non-Small Cell Lung Cancer><Non-Small-Cell Lung Carcinoma><Oncogene ErbB2><Oncology><Oncology Cancer><P30 Award><P30 Grant><P30 Mechanism><P30 Program><Participant><Patients><Persons><Ph.D.><PhD><Phase><Principal Investigator><Pulmonary Cancer><Pulmonary malignant Neoplasm><Research><Research Personnel><Researchers><Review Committee><Role><SWOG><Safety><Scientific Advances and Accomplishments><Southwest Oncology Group><TKR1><Thoracic Oncology><Trastuzumab><Work><Workshop><c-erb-2 Monoclonal Antibody><c-erbB-2><c-erbB-2 Genes><c-erbB-2 Proto-Oncogenes><career><clinical trial participant><drug development><early clinical trial><early phase clinical trial><erbB-2 Genes><herstatin><improved><innovate><innovation><innovative><investigator-initiated trial><lung cancer><malignancy><medical college><medical schools><member><neoplasm/cancer><neu Genes><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><oncology trial><patient centered><patient oriented><patient population><pulmonary><rhuMAb HER2><school of medicine><scientific accomplishments><scientific advances><social role>